Double-hit B-cell lymphomas.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-02-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2010-09-297879PMID 21119107
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

  2012cited by this paper
• Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B‐cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

  2012cited by this paper
• B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma

  2012influential reference
• B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome

  2012cited by this paper
• B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma

  2010influential reference
• Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.

  2010cited by this paper
• MiRNA profiling in B non‐Hodgkin lymphoma: a MYC‐related miRNA profile characterizes Burkitt lymphoma

  2010cited by this paper
• Mature B‐ and T‐cell neoplasms and Hodgkin lymphoma

  2010influential reference
• Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas

  2010cited by this paper
• IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas

  2010influential reference
• Pediatric follicular lymphoma – a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin’s Lymphoma - Berlin-Frankfurt-Münster (NHL-BFM) multicenter trials

  2010cited by this paper
• Advances in the understanding of MYC‐induced lymphomagenesis

  2010influential reference
• Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment

  2009cited by this paper
• Mechanisms promoting translocations in editing and switching peripheral B cells

  2009influential reference
• Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations

  2009cited by this paper
• MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.

  2009cited by this paper
• Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.

  2009cited by this paper
• Clinical significance of 8q24/c‐MYC translocation in diffuse large B‐cell lymphoma

  2009cited by this paper
• Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations

  2009influential reference
• AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations.

  2009influential reference
• BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma

  2009influential reference
• t(11;14)-positive clones can persist over a long period of time in the peripheral blood of healthy individuals

  2009cited by this paper
• Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

  2009cited by this paper
• The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

  2009influential reference
• BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome.

  2009cited by this paper
• Reply to: [Comment to: The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92:1335-1342

  2008cited by this paper
• Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway.

  2008influential reference
• Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt’s lymphoma

  2008cited by this paper
• Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials.

  2008cited by this paper
• The most frequent t(14;19)(q32;q13)-positive B-cell malignancy corresponds to an aggressive subgroup of atypical chronic lymphocytic leukemia

  2008cited by this paper
• Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching

  2008influential reference
• AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations.

  2008influential reference
• Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity.

  2008influential reference
• Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells.

  2008influential reference
• Widespread microRNA repression by Myc contributes to tumorigenesis

  2008cited by this paper
• C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator?

  2008cited by this paper
• Comment to: The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007; 92:1335-1342

  2008cited by this paper
• Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways

  2008cited by this paper
• Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge

  2008cited by this paper
• Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques

  2008influential reference
• Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

  2008cited by this paper
• Blastic mantle cell lymphoma with a Burkitt translocation

  2008cited by this paper
• Transformation of follicular lymphoma to precursor B-cell lymphoblastic lymphoma with c-myc gene rearrangement as a critical event.

  2008cited by this paper
• c-Myc: linking transformation and genomic instability.

  2008influential reference
• Structure and consequences of IGH switch breakpoints in Burkitt lymphoma.

  2008influential reference
• MYC translocation‐negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation

  2008cited by this paper
• Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice.

  2008influential reference
• MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) type

  2008cited by this paper
• A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

  2008cited by this paper
• Translocations Involving 8q24 in Burkitt Lymphoma and Other Malignant Lymphomas : A Historical Review of Cytogenetics in the Light of Todays Knowledge

  2008cited by this paper
• A role for AID in chromosome translocations between c-myc and the IgH variable region

  2007influential reference
• Repression of BCL-6 is required for the formation of human memory B cells in vitro

  2007influential reference
• A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma.

  2007influential reference
• BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.

  2007influential reference
• Histopathology and immunohistochemistry in distinguishing Burkitt lymphoma from diffuse large B-cell lymphoma with very high proliferation index and with or without a starry-sky pattern: a comparative study with EBER and FISH.

  2007cited by this paper
• Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors.

  2007cited by this paper
• A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation

  2007cited by this paper
• Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas

  2007influential reference
• The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement

  2007cited by this paper
• A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

  2006cited by this paper
• Distinguishing primary and secondary translocations in multiple myeloma.

  2006cited by this paper
• Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis

  2006cited by this paper
• Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

  2006cited by this paper
• Molecular diagnosis of Burkitt's lymphoma.

  2006cited by this paper
• Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals

  2006cited by this paper
• The c-Myc target gene network.

  2006cited by this paper
• Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: Implications for lymphomagenesis

  2006cited by this paper
• Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis

  2006influential reference
• Presence of somatic hypermutation and activation‐induced cytidine deaminase in acute lymphoblastic leukemia L2 with t(14;18)(q32;q21)

  2005cited by this paper
• Clinical, Immunophenotypic, and Genetic Analysis of Adult Lymphomas With Morphologic Features of Burkitt Lymphoma

  2005cited by this paper
• c-Myc-regulated microRNAs modulate E2F1 expression

  2005cited by this paper
• Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice.

  2005influential reference
• The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

  2004influential reference
• Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

  2004cited by this paper
• Direct Repression of prdm1 by Bcl-6 Inhibits Plasmacytic Differentiation1

  2004cited by this paper
• Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study

  2004cited by this paper
• Burkitt Transformation of Mantle Cell Lymphoma

  2004cited by this paper
• AID is required for c-myc/IgH chromosome translocations in vivo.

  2004cited by this paper
• The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

  2003cited by this paper
• Correspondence re: Welzel et al, Cancer Res, 61: 1629-1636.

  2003cited by this paper
• Transcriptional analysis of the B cell germinal center reaction

  2003cited by this paper
• Follicular lymphoma with a novel t(14;18) breakpoint involving the immunoglobulin heavy chain switch mu region indicates an origin from germinal center B cells.

  2002influential reference
• Cytogenetic Analysis in Mantle Cell Lymphoma: A Review of 214 Cases

  2002influential reference
• Mantle Cell Lymphoma with 8q24 Chromosomal Abnormalities: a Report of 5 Cases with Blastoid Features

  2002cited by this paper
• In situ localization of follicular lymphoma: description and analysis by laser capture microdissection.

  2002influential reference
• Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation.

  2002cited by this paper
• Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma.

  2001cited by this paper
• Chromosome translocations in multiple myeloma

  2001cited by this paper
• Molecular features of B-cell lymphoma

  2001cited by this paper
• Novel Insights into the Mechanism of t(14;18)(q32;q21) Translocation in Follicular Lymphoma

  2001influential reference
• Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant.

  2001cited by this paper
• BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.

  2000influential reference
• Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14;18) translocation.

  2000influential reference
• 8q24 translocations in blastic transformation of mantle cell lymphoma.

  2000cited by this paper
• Concurrent activation of a novel putative transforming gene, myeov, and cyclin D1 in a subset of multiple myeloma cell lines with t(11;14)(q13;q32).

  2000cited by this paper
• Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation.

  1999cited by this paper
• De novo CD5+ Burkitt lymphoma/leukemia.

  1999cited by this paper
• High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.

  1998influential reference
• Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice

  1998cited by this paper
• Control of inflammation, cytokine expression, and germinal center formation by BCL-6.

  1997influential reference

• Burkitt Lymphoma-A Guide to Biological Features, Diagnosis and Differential Diagnosis.

  2026cites this paper
• Outcome of high-grade B-cell lymphoma compared to other large B-cell lymphoma after CAR-T rescue. A DESCAR-T LYSA study.

  2025cites this paper
• Investigation into the prognostic factors of early recurrence and progression in previously untreated diffuse large B-cell lymphoma and a statistical prediction model for POD12

  2025cites this paper
• Overcoming CAR-T bottlenecks in high-risk DLBCL: a molecular subtyping enhancement strategy

  2025cites this paper
• High-grade B-cell lymphomas: high difficulties to diagnose and treat?

  2025cites this paper
• SOHO State of the Art Updates and Next Questions | Diagnosis and Management of High-Grade B-Cell Lymphomas.

  2025cites this paper
• Leukemic Phase of MYC/BCL2 Double-Hit High-grade B-cell Lymphoma: A report of 35 cases.

  2025cites this paper
• Interaction between stromal cells and tumor cells promotes the GCB-DLBCL cell survival via CD40/RANK-KDM6B-NF-κB axis.

  2025cites this paper
• MYC networks associate with decreased CD8 T-cell presence in diffuse large B-cell lymphoma and may be addressed by the synergistic combination of AZD4573 and Selinexor – a preliminary analysis

  2025cites this paper
• Enforced MYC expression directs a distinct transcriptional state during plasma cell differentiation

  2025cites this paper
• Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL)

  2025cites this paper
• Racial Differences in the Molecular Genetic Biomarkers of Diffuse Large B-Cell Lymphoma

  2025cites this paper
• Fifth edition WHO classification: mature B-cell neoplasms

  2025cites this paper
• Hi-C Technology Reveals Actionable Gene Fusions and Rearrangements in Diffuse Large B-Cell Lymphoma Unidentified by Conventional FISH

  2025cites this paper
• EBER-Negative, Double-Hit High-Grade B-Cell Lymphoma Responding to Methotrexate Discontinuation.

  2024cites this paper
• Diverse B-cell tumors associated with t(14;19)(q32;q13)/IGH::BCL3 identified by G-banding and fluorescence in situ hybridization

  2024cites this paper
• Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis

  2024cites this paper
• How lactate affects immune strategies in lymphoma

  2024cites this paper
• MRI-based radiomics virtual biopsy for BCL6 in primary central nervous system lymphoma.

  2024cites this paper
• The prognostic significance of MYC/BCL2 double expression in DLBCL in the genetic classification era

  2024cites this paper
• Navigating Lymphomas through BCR Signaling and Double-Hit Insights: Overview

  2024cites this paper
• Delineating MYC-Mediated Escape Mechanisms from Conventional and T Cell-Redirecting Therapeutic Antibodies

  2024cites this paper
• Effect of P53 expression on double-expressor lymphoma and characteristics of DLBCL Co-expressing P53 and MYC: Clinical, pathological, and biological insights.

  2024cites this paper
• NAALADL2-AS2 functions as a competing endogenous RNA to regulate apoptosis and drug resistance in DLBCL

  2024cites this paper
• Mapping the cellular landscape of Atlantic salmon head kidney by single cell and single nucleus transcriptomics.

  2024cites this paper
• Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (DLBCL NOS) Presenting as Multiple Subcutaneous Nodules: An Unusual Cutaneous Presentation of Systemic Disease

  2023cites this paper
• The significance of upfront autologous stem cell transplantation for high‐intermediate/high‐risk stage IV diffuse large B‐cell lymphoma

  2023cites this paper
• High-Grade B-Cell Lymphoma With Malignant Effusions as the Initial Presentation.

  2023cites this paper
• MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study

  2023cites this paper
• Chromosomal Aberration t(14;17)(q32;q21) Simultaneously Activates HOXB5 and miR10a in Triple-Hit B-Cell Lymphoma

  2023cites this paper
• Epstein–Barr Virus and the Pathogenesis of Diffuse Large B-Cell Lymphoma

  2023cites this paper
• Aggressive B-cell non-Hodgkin lymphomas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology

  2023cites this paper
• Lack of reproducibility of histopathological features in MYC‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium

  2023cites this paper
• Identification of a novel model based on ferroptosis-related genes for predicting the prognosis of diffuse large B-cell lymphomas

  2023cites this paper
• Double-hit and double-expressor primary central nervous system lymphoma: Experience from North India of an infrequent but aggressive variant

  2023cites this paper
• Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study

  2023cites this paper
• Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma

  2023cites this paper
• Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms—Updated Classification and New Concepts

  2023cites this paper
• Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies

  2023cites this paper
• A case of triple hit lymphoma and rapid deterioration

  2023cites this paper
• Cytogenetics in the management of mature B-cell non-Hodgkin lymphomas: Guidelines from the Groupe Francophone de Cytogénétique Hematologique (GFCH).

  2023cites this paper
• Primary Splenic Diffuse Large B-Cell Lymphoma: A Case Report

  2023cites this paper
• Progression of follicular lymphoma and related entities: Report from the 2021 SH/EAHP Workshop.

  2023cites this paper
• Cytomorphologic, immunophenotypic, and cytogenetic spectrum in a MYC/BCL2 double-hit high-grade B-cell lymphoma

  2022cites this paper
• Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma

  2022cites this paper
• Relationship between C-MYC, BCL-2 and BCL-6 Genetic Abnormalities and Bone Marrow Biopsy in B-Non-Hodgkin Lymphoma

  2022cites this paper
• High-Grade B-cell Lymphomas

  2022cites this paper
• MYC/BCL2 double- and MYC/BCL2/BCL6 triple-hit follicular lymphomas associated with t(8;14;18)(q24;q32;q21)

  2022cites this paper
• Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance

  2022cites this paper
• Classifying Germinal Center Derived Lymphomas—Navigate a Complex Transcriptional Landscape

  2022cites this paper
• Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma

  2022cites this paper
• DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis

  2022cites this paper
• Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System

  2022cites this paper
• Immunophenotypic transformation in relapsed/refractory mantle cell lymphoma treated with human anti-CD5 chimeric antigen receptor T cells: A Case Report

  2022influential citation
• Clinical and Pathological Features of Double-Hit and Triple-Hit High-Grade B-Cell Lymphomas: A Retrospective Study from Three Portuguese Tertiary Centers

  2022cites this paper
• A comprehensive modular map of Diffuse Large B-cell Lymphoma

  2022cites this paper
• HIV-associated DLBCL: Clinicopathological factors including dual-colour chromogenic in situ hybridisation to assess MYC gene copies.

  2022cites this paper
• Therapeutic efficacy of an injectable formulation of purinostat mesylate in SU-DHL-6 tumour model

  2022cites this paper
• A comprehensive modular map of Diffuse Large B-cell 1 Lymphoma 2

  2022cites this paper
• Prognostic Nutritional Index Predicts Early Mortality in Diffuse Large B-cell Lymphoma

  2022cites this paper
• Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group

  2022cites this paper
• The Methylation of the p53 Targets the Genes MIR-203, MIR-129-2, MIR-34A and MIR-34B/C in the Tumor Tissue of Diffuse Large B-Cell Lymphoma

  2022cites this paper
• Evaluation of the prognostic value of the metabolic volumetric parameters calculated with 18F-FDG PET/CT and its value added to the molecular characteristics in patients with diffuse large B-cell lymphoma.

  2022cites this paper
• INVESTIGATION OF HISTOPATHOLOGICAL AND IMMUNOHISTOCHEMICAL FEATURES OF PATIENTS WITH NON-HODGKIN LYMPHOMA

  2022cites this paper
• Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma.

  2022cites this paper
• Targeting MYC and BCL2 by a natural compound for “double‐hit” lymphoma

  2022cites this paper
• Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma

  2022cites this paper
• c‐MYC and p53 expression highlight starry‐sky pattern as a favourable prognostic feature in R‐CHOP‐treated diffuse large B‐cell lymphoma

  2021influential citation
• Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing

  2021cites this paper
• High-grade B-cell lymphoma accompanied with MYC and BCL2 and/or BCL6 rearrangements

  2021cites this paper
• Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms

  2021cites this paper
• Genome instability and lymphoma.

  2021cites this paper
• Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications

  2021cites this paper
• The Identi cation and Analysis of a Novel Model Based on Ferroptosis-Related Genes for Predicting the Prognosis of Diffuse Large B-Cell Lymphomas

  2021cites this paper
• Prognostication of Primary Tumor Location in Early-Stage Nodal Diffuse Large B-Cell Lymphoma: An Analysis of the SEER Database

  2021cites this paper
• Clinical utility of brain biopsy for presumed CNS relapse of systemic lymphoma.

  2021cites this paper
• Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment

  2021cites this paper
• MYC/BCL2/BCL6 triple hit and TP53 deletion in a case of high-grade B cell lymphoma receiving CAR T cell immunotherapy

  2021cites this paper
• Resistant rhinosinusitis?

  2021cites this paper
• High performance of multiplex fluorescence in situ hybridization to simultaneous detection of BCL2 and BCL6 rearrangements: useful application in the characterization of DLBCLs

  2021cites this paper
• Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features

  2021cites this paper
• High-Grade B-Cell Lymphoma (HGBL) with MYC and BCL2 and/or BCL6 Rearrangements Is Predominantly BCL6-Rearranged and BCL6-Expressing in Taiwan

  2021influential citation
• A Review of Results from Clinical Trials Based on Co-Variants of the R-CHOP Regimen in Untreated Patients with Diffuse Large B-cell Lymphoma

  2021cites this paper
• Significance of Single-cell Level Dual Expression of BCL2 and MYC Determined With Multiplex Immunohistochemistry in Diffuse Large B-Cell Lymphoma

  2021cites this paper
• Une rhinosinusite résistante ?

  2021cites this paper
• Development and validation of prognostic scoring in primary intestinal diffuse large B-cell lymphoma: a single-institution study of 184 patients

  2021cites this paper
• t(9;14)(p13;q32)/ PAX5 -IGH translocation as a secondary cytogenetic abnormality in diffuse large B-cell lymphoma

  2021cites this paper
• Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?

  2021cites this paper
• A novel CRISPR activation mouse enables modelling of aggressive lymphoma and interrogation of venetoclax resistance.

  2021cites this paper
• BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival

  2021cites this paper
• B-Cell Precursor Acute Lymphoblastic Leukaemia/Lymphoma with Myc and Bcl-2 Rearrangements, a Case Report of an Unclassified “New” Entity

  2021cites this paper
• Clinical Implications of a Targeted RNA Sequencing Panel in the Detection of Gene Fusions in Solid Tumors.

  2021cites this paper
• EBV+ high‐grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements: a multi‐institutional study

  2021influential citation
• Primary Thyroid Diffuse Large B-cell Lymphoma in a Child with Hashimoto’s Thyroiditis: A Case Report

  2021cites this paper
• C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases

  2020cites this paper
• Double-hit monomorphic B-cell lymphoma after liver transplantation

  2020cites this paper
• Double Hit and Double Expresser Diffuse Large B Cell Lymphoma Subtypes: Discrete Subtypes and Major Predictors of Overall Survival

  2020cites this paper
• Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma

  2020cites this paper
• Primary pulmonary diffuse large B-cell lymphoma with multiple ground-glass nodules as the primary manifestation

  2020cites this paper
• Navigating the Jargon of Molecular Testing in Non-Hodgkin Lymphoma

  2020cites this paper